Pharmaceutical News

RSS

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

In a unique partnership, Zydus, India's fourth largest healthcare group and an innovation-led global healthcare provider, and IDRI, a Seattle-based non-profit research and product development organization, announced today they are collaborating on the production and clinical development of IDRI's visceral leishmaniasis vaccine candidate, designed to prevent the deadly parasitic disease.

26 Jul 2013

Researchers explain how gut bacteria can inactivate cardiac drugs

For decades, doctors have understood that microbes in the human gut can influence how certain drugs work in the body - by either activating or inactivating specific compounds, but questions have long remained about exactly how the process works.

26 Jul 2013

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.

25 Jul 2013

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Study findings published online, ahead of print, in Cornea show that daily dietary supplementation with a unique combination of omega fatty acids (GLA, EPA and DHA) for six months is effective in improving ocular irritation symptoms and halting the progression of inflammation that characterizes moderate to severe dry eye.

25 Jul 2013

Novo Solutions MD announces releases of NovoScarMD scar cream

Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury

25 Jul 2013

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

Mylan Inc. today confirmed that Mylan Pharmaceuticals Inc. and Orion Corporation have entered into a settlement and license agreement settling the parties litigation in connection with Mylan's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Carbidopa/Levodopa/Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg.

25 Jul 2013

Combination treatment can reduce hepatitis C infection in people who inject drugs

The burden of liver disease could be dramatically reduced by scaling up the combination of interventions for hepatitis C infection among people who inject drugs according to University of Bristol researchers. The findings, published today [24 July], form part of new global recommendations on treating the virus.

25 Jul 2013

Stopping cholesterol drugs may increase risk of Parkinson's disease

People who stop taking cholesterol drugs may be at an increased risk for developing Parkinson's disease, according to research that appears in the July 24, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

25 Jul 2013

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.

24 Jul 2013

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma, a rare form of lung cancer.

24 Jul 2013

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with OSI, Pfizer and Genentech that will resolve patent litigation related to Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg.

24 Jul 2013

Cambridge Consultants help Clinigen Group to breathe new life into old drugs

Innovative product development and technology consultancy firm Cambridge Consultants has collaborated with Clinigen Group to create a new way of identifying fresh market applications for drugs nearing the end of their product lifecycle.

From Clinigen Group 24 Jul 2013

Baylor Research Institute, Novartis sign license agreement for canakinumab

Baylor Research Institute, the research arm of Baylor Health Care System, announced that it has signed an agreement with Novartis to non-exclusively license Baylor's patents pertaining to the treatment of Systemic Onset Juvenile Idiopathic Arthritis using interleukin-1 beta antagonists.

24 Jul 2013

3-D hydrogel approach to study aggressive and deadly forms of brain cancer

Human glioblastoma multiforme, one of the most common, aggressive and deadly forms of brain cancer, is notoriously difficult to study. Scientists have traditionally studied cancer cells in petri dishes, which have none of the properties of the brain tissues in which these cancers grow, or in expensive animal models.

24 Jul 2013

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

The first large non-commercial clinical study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS), shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

24 Jul 2013

NIH awards $2.35M grant to BUSM researcher to study the development of gonococcal vaccine

Lee Wetzler, MD, an attending physician in the department of infectious diseases at Boston Medical Center and associate program director for research in the section of infectious diseases at Boston University School of Medicine (BUSM), was awarded a four-year, $2.35 million grant from the National Institutes of Health (NIH) to study the development of a gonococcal vaccine.

24 Jul 2013

Pharmaceutical News

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Zydus, IDRI partner to develop visceral leishmaniasis vaccine candidate

Researchers explain how gut bacteria can inactivate cardiac drugs

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Novo Solutions MD announces releases of NovoScarMD scar cream

Mylan, Orion sign settlement, license agreement for generic version of STALEVO

Combination treatment can reduce hepatitis C infection in people who inject drugs

Stopping cholesterol drugs may increase risk of Parkinson's disease

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Mylan Pharmaceuticals agrees to resolve patent litigation related to Erlotinib Hydrochloride Tablets

Cambridge Consultants help Clinigen Group to breathe new life into old drugs

Baylor Research Institute, Novartis sign license agreement for canakinumab

3-D hydrogel approach to study aggressive and deadly forms of brain cancer

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

NIH awards $2.35M grant to BUSM researcher to study the development of gonococcal vaccine

FDA takes action to remove illegal diabetes products from market

First Edition: July 23, 2013

Discovery may help explain how anti-inflammatory steroid drugs work

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News